Allergan

FDA's orphan drug program under GAO scrutiny after senators allege abuse

Eli Lilly says it's cutting an average of 50% off list prices—and its price hikes don't work

Allergan, Teva claim top spots in GAAP vs. non-GAAP hall of shame: report

Allergan urges dry-eye sufferers to pump up their eye power

Surprised shareholders target Allergan over generics pricing probe